Aidoc, a global leader in enterprise-scale clinical AI focused on helping physicians make earlier, safer diagnoses by turning raw patient signals into actionable insight, raised $150 million in a Series E funding round.
Growth Equity at Goldman Sachs Alternatives led the investment round with participation from General Catalyst, SoftBank Investment Advisors, and NVentures (NVIDIA’s venture capital arm).
Including the latest funding round, Aidoc has raised over $500 million to date.
“By 2030, every complex diagnostic decision should be supported by AI that enables earlier detection and reduces preventable error,” said Elad Walach, co-founder and CEO of Aidoc.
“We feel a deep responsibility to deploy CARE (Clinical AI Reasoning Engine) safely and at scale across health systems. This funding accelerates comprehensive disease coverage and advances end-to-end AI across CT and X-ray, spanning the full workflow, including pixel to draft report within two years,” added Elad Walach.
The new capital will support further development of Aidoc’s CARE foundation model, expansion into additional clinical indications, and new capabilities such as automated imaging draft report creation to power end-to-end clinical AI workflows. It will also drive broader global deployment of its aiOS enterprise AI platform as hospitals consolidate standalone tools under centralized operating frameworks designed to manage and govern AI at scale.
Earlier this year, CARE received a landmark first FDA clearance for a comprehensive double-digit foundation model-based triage system in clinical imaging. Today, Aidoc’s technology has analyzed more than 110 million patient cases and is deployed in nearly 2,000 hospitals worldwide, supporting clinical decision-making for approximately 60 million patients each year.
Diagnostic errors and delays contribute to at least 400,000 deaths each year in the United States, driven by rising imaging volumes, workforce shortages, and growing clinical complexity. While AI has long promised to reduce that burden, most tools have tackled one use case at a time, limiting their impact at scale.
Digital health companies, including clinical AI startups, have secured more than $180 billion in funding to date, according to our recent 2026 Funding Database.
The funding activity is largely driven by AI-driven digital health startups in 2026. Notable recent funding rounds include:
- Dehaze, a Germany–based healthtech startup developing a foundational AI model for chronic disease detection, raised €3.2 million in a Seed funding round.
- Almanac Health, a provider of an AI-powered point of care evidence-based clinical decision support platform for healthcare providers, raised $10 million in Seed funding.
- Ambient Clinical Analytics, a provider of a data-driven, FDA Class II-cleared and CE-marked clinical decision support (CDS) platform for healthcare providers, raised $5 million in a strategic funding round led by Mairs & Power Venture Capital.